复方苦参注射液联合奥沙利铂对结肠癌肿瘤细胞的杀伤与增殖作用研究

Effects of the compound Kushen Injection and oxaliplatin on the killing and proliferation of colon cancer cells

目的研究复方苦参注射液、奥沙利铂以及两药联合对结肠癌细胞增殖的影响。方法将结肠癌SW620、HT29、LOVO细胞株细胞分为4组:空白对照组(等量的普通培养液)、阴性对照组(等量的普通培养液和预实验组等量的结肠癌细胞)、6个浓度(5,10,20,30,40,50μL·m L^-1)复方苦参注射液组(即复方苦参-A组、复方苦参-B组、复方苦参-C组、复方苦参-D组、复方苦参-E组、复方苦参-F组)、6个浓度(1,5,10,20,30,40μL·m L^-1)奥沙利铂组(即奥沙利铂-A组、奥沙利铂-B组、奥沙利铂-C组、奥沙利铂-D组、奥沙利铂-E组、奥沙利铂-F组)和联合组(5,10,20,30,40,50μL·m L^-1复方苦参注射液+40μg·m L^-1奥沙利铂,即联合组-A组、联合组-B组、联合组-C组、联合组-D组、联合组-E组、联合组-F组)。各组分别处理SW620、HT29和LOVO结肠癌细胞。用细胞增殖活性检测法(CCK-8)检测细胞增殖。结果SW620细胞:空白对照组、阴性对照组和复方苦参-A、-B、-C、-D、-E、-F组的细胞增殖水平(OD值)分别为(5.32±0.13)×10-2,(27.07±0.74)×10-3,(27.00±0.11)×10-2,(12.63±0.11)×10-2,(9.77±0.59)×10-2,(8.69±0.92)×10-3,(7.42±0.43)×10-2和(6.21±0.11)×10-2;空白组、阴性对照组和奥沙利铂-A、-B、-C、-D、-E和-F组的细胞增殖水平(OD值)分别为(4.93±0.28)×10-2,(41.39±0.22)×10-2,(23.29±0.60)×10-2,(13.50±0.36)×10-2,(11.08±0.66)×10-2,(9.68±0.35)×10-3,(8.50±0.19)×10-2和(7.83±0.34)×10-2;6个浓度复方苦参组和6个浓度奥沙利铂组与阴性对照组相比,差异均有统计学意义(均P<0.01),且随着药物浓度的增加细胞增殖水平逐渐减小。SW620细胞:空白组、阴性对照组和联合组-A、-B、-C、-D、-E和-F组的细胞增殖水平(OD值)分别为(6.45±0.14)×10-2,(39.69±0.17)×10-2,(9.21±0.20)×10-2,(8.84±0.98)10-3,(8.30±0.12)×10-2,(8.16±0.15)×10-2,(7.64±0.20)×10-2,(7.47±0.14)×10-2。联合组与复方苦参组和奥沙利铂组相比,差异均有统计学意义(均P<0.05)。HT29、LOVO细胞结果的趋势与SW620细胞类似。结论复方苦参注射液、奥沙利铂以及两药联用对结肠癌细胞均有体外杀伤作用,且具有剂量依赖性。

Objective To study the effects of Compound Kushen Injection(CKI),oxaliplatin and combined with two drugs on the proliferation of colon cancer cells.Methods The colon cancer cell lines SW620,HT29 and LOVO were divided into four groups as the following:blank control group(only ordinary culture medium),negative control group(pre-experimental colon cancer cell lines were cultivated with ordinary culture medium),CKI group(based on negative control group,different concentration of CKI were given at the level of 5,10,20,30,40,50μL·mL^-1,which were named as CKI-A,CKI-B,CKI-C,CKI-D,CKI-E,and CKI-F groups,respectively),oxaliplatin group(based on negative control group,different concentration of oxaliplatin were given at the level of 1,5,10,20,30,40μL·mL^-1,which were named as oxaliplatin-A,oxaliplatin-B,oxaliplatin-C,oxaliplatin-D,oxaliplatin-E,and oxaliplatin-F groups,respectively).The combined(CKI+oxaliplatin)group(based on compound CKI group,colon cancer cells were treated with 40μL·mL^-1 oxaliplatin,which were named as combination-A,combination-B,combination-C,combination-D,combination-E,and combination-F groups,respectively).SW620,HT29 and LOVO colon cancer cells were treated respectively according upper methods,and their cell proliferation was detected by CCK-8 assay.Results SW620 cells:the cell proliferation level(OD value)in blank control group,negative control group,and CKI-A,CKI-B,CKI-C,CKI-D,CKI-E,and CKI-F groups were(5.32±0.13)×10^-2,(27.07±0.74)×10^-3,(27.00±0.11)×10^-2,(12.63±0.11)×10^-2,(9.77±0.59)×10^-2,(8.69±0.92)×10^-3,(7.42±0.43)×10^-2,(6.21±0.11)×10^-2,respectively;the cell proliferation level(OD value)in blank group,negative control group,and oxaliplatin-A,oxaliplatin-B,oxaliplatin-C,oxaliplatin-D,oxaliplatin-E,and oxaliplatin-F groups were(4.93±0.28)×10^-2,(41.39±0.22)×10^-2,(23.29±0.60)×10^-2,(13.50±0.36)×10^-2,(11.08±0.66)×10^-2,(9.68±0.35)×10^-3,(8.50±0.19)×10^-2,(7.83±0.34)×10^-2,respectively;comparison between six concentration CKI groups,six concentration oxaliplatin groups with the negative control group,the difference were significantly(all P<0.01);the OD value were decreased gradually with the increase of drug concentration.SW620 cells:the cell proliferation level(OD value)in blank control group,negative control group,and combination-A,combination-B,combination-C,combination-D,combination-E,and combination-F groups were(6.45±0.14)×10^-2,(39.69±0.18)×10^-2,(9.21±0.20)×10^-2,(8.84±0.98)×10^-3,(8.30±0.12)×10^-2,(8.16±0.15)×10^-2,(7.64±0.20)×10^-2,(7.47±0.14)×10^-2,respectively;comparison combination groups with CKI groups and oxaliplatin groups,the difference were significantly(all P<0.05).The trend of the results of HT29 and LOVO cells were similar with those of SW620 cells.Conclusion CIK,oxaliplatin and their combination can kill colon cancer cells in vitro in a dose-dependent manner.